Thomas Newgarden

Thomas Newgarden (Director) bought 14,000 shares at $15.21 avg; now -23.4% from 52-week high and below transaction price.

Thomas Newgarden completed 2 separate purchases totaling 14,000 shares for $212,957.60 at an average price of $15.21, increasing his holdings by +16.4% to 99,366 shares post-transaction. The purchases occurred on consecutive days (2026-05-28 and 2026-05-29) at prices of $15.50 and $14.99, during a period when the stock was already -12.3% over 30 days and -9.8% over 90 days. The current price of $14.87 is now below both transaction prices and -23.4% from the 52-week high of $19.42. His same-ticker history shows mixed timing: 3 of 5 prior KINS purchases resulted in positive 90-day returns, but the most recent two purchases (2026-05-13 and 2026-05-12) have shown only modest 30-day and 90-day gains of +3.6% and +2.4% respectively, suggesting recent buys at this ticker have underperformed. The purchases come while the company reports quarterly net income of $-5,808,250.00, and the insider's accumulation into a declining stock in a loss-making period merits observation of whether this represents conviction or automated execution.

Director Newgarden Thomas purchased 30,502 shares at $14.36–$14.52 over two days as stock trades well below 52-week highs; he has a mixed track record at this ticker.

Newgarden Thomas, a director at Kingstone Companies, made consecutive purchases totaling over 30,000 shares over two trading days, bringing his stake up significantly while the stock trades roughly 37% below its 52-week high and has declined over the past month. This is his seventh open-market purchase in three years, continuing a pattern of accumulation with no offsetting sales, though his track record at this specific ticker is mixed—three of his five prior purchases at Kingstone delivered gains within both the near and longer term, while two preceded stock declines. The company itself remains profitable with strong annual revenue growth, and the latest quarterly results show a net loss, though the stock's current valuation appears modest. Newgarden's willingness to deploy capital repeatedly into the same company at depressed prices suggests ongoing conviction, but the mixed outcomes from his prior timing at this ticker—not all of which paid off—warrant monitoring rather than automatic endorsement of his judgment on this stock.

KINS Director Newgarden Thomas buys 12,500 shares at $16.77; 4th purchase in 9 days amid continued conviction after +31.6% to +38.0% 90d returns on prior buys.

Newgarden Thomas purchased 12,500 shares of Kingstone at $16.77, adding to an accumulation pattern: he executed four separate buys at KINS in 9 days (May 19–27, 2025), totaling material size relative to his prior holdings of 39.2K shares. His same-ticker history shows three prior measurable buys at KINS delivered 90d returns of +31.6%, +33.6%, and +38.0%, all well-timed (the stock rose after each purchase). His cross-ticker track record across all tickers is equally strong: 4 prior buys averaged +34.4% over 30 days and +40.9% over 90 days with a 100.00% win rate. The current stock price of $16.56 is 23.6% below the 52-week high of $21.67, and over the 90-day span it has gained +8.4%, consistent with the insider's demonstrated ability to identify entry points. At a P/E of 11.11 and market cap of $231.9M against quarterly revenue of $50.5M and net income of $3.9M, the fundamentals show a modestly profitable, growing business (FY revenue growth +7.6%). The rapid succession of purchases suggests continued conviction rather than isolated opportunism.

Director Thomas Newgarden bought 11,000 shares of KINS at $16.11; prior 3 KINS buys all showed +31.6% to +50.1% 90-day returns.

Newgarden's purchase of 11,000 shares (39% increase to his 39,215 share position) follows a precise timing pattern observed in his prior KINS activity. His three previous purchases at this ticker on 2024-11-19, -20, and -21 each produced strong 90-day returns: +50.1%, +35.9%, and +36.6% respectively. The current transaction at $16.11 occurs as the stock trades at $15.63, down 9.3% over 30 days and 27.9% below the 52-week high, creating a statistical context similar to his prior entry points. The company shows modest fundamentals with a P/E of 10.49, $50.5M quarterly revenue, and 7.6% annual growth, positioning the stock modestly—neither distressed nor expensive. His track record across tickers (3 prior buys, 100% 90-day win rate, +40.9% average 90d return) combined with three consecutive well-timed entries at KINS warrants attention to whether this buy reflects renewed conviction or adherence to a recurring pattern.

Director Newgarden buys 15,112 shares across 3 transactions ($194.5K) as KINS approaches 52-week high; cluster pattern with 3 other insiders in past 14 days.

Director Thomas Newgarden acquired 15,112 shares in 3 separate purchases over three trading days (Nov 19-21), with prices ranging from $11.94 to $13.45 and a blended average of $12.87, expanding his holdings by 157.2% from 9,614 to 24,726 shares. The stock currently trades at $13.83, near its 52-week high of $13.90 (-0.5%), and has surged 39.8% over 30 days and 47.8% over 90 days, suggesting the purchases occurred during a strong uptrend. Notably, a cluster of 3 other insiders also bought within the past 14 days, indicating concurrent accumulation across the insider group. The company reported positive near-term results—$7.0M net income in the latest quarter and 10.8% annual revenue growth—though it was unprofitable over its most recent full fiscal year, creating a mixed fundamental backdrop for the timing of these acquisitions.